InvestorsHub Logo
Followers 33
Posts 2854
Boards Moderated 1
Alias Born 10/24/2015

Re: None

Thursday, 04/30/2020 6:58:56 PM

Thursday, April 30, 2020 6:58:56 PM

Post# of 977
ASCO: Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma